2,709 Shares in Penumbra, Inc. $PEN Acquired by Two Sigma Securities LLC

Two Sigma Securities LLC acquired a new position in shares of Penumbra, Inc. (NYSE:PEN) during the second quarter, Holdings Channel.com reports. The institutional investor acquired 2,709 shares of the company’s stock, valued at approximately $855,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Penumbra during the 2nd quarter worth $25,000. Larson Financial Group LLC increased its position in Penumbra by 4,100.0% during the fourth quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock worth $26,000 after purchasing an additional 82 shares during the last quarter. CIBC Private Wealth Group LLC raised its stake in Penumbra by 2,700.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company’s stock worth $26,000 after purchasing an additional 81 shares during the period. Motiv8 Investments LLC purchased a new position in Penumbra during the fourth quarter worth about $27,000. Finally, Keating Financial Advisory Services Inc. acquired a new position in Penumbra in the 2nd quarter valued at about $31,000. 88.88% of the stock is owned by institutional investors and hedge funds.

Penumbra Price Performance

PEN opened at $322.80 on Wednesday. The stock’s 50-day moving average price is $320.94 and its 200 day moving average price is $326.55. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $362.41. The firm has a market cap of $12.72 billion, a price-to-earnings ratio of 79.31, a PEG ratio of 2.03 and a beta of 0.70. The company has a current ratio of 5.75, a quick ratio of 3.86 and a debt-to-equity ratio of 0.01.

Penumbra (NYSE:PEN) last released its earnings results on Thursday, July 30th. The company reported $0.88 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.28). The firm had revenue of $390.05 million during the quarter, compared to analyst estimates of $389.64 million. Penumbra had a net margin of 10.67% and a return on equity of 10.50%. The business’s revenue was up 14.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.86 earnings per share. As a group, sell-side analysts expect that Penumbra, Inc. will post 4.96 earnings per share for the current year.

Analyst Ratings Changes

PEN has been the subject of several analyst reports. Wall Street Zen raised shares of Penumbra to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Penumbra in a research report on Friday, July 17th. Royal Bank Of Canada reissued a “sector perform” rating and set a $374.00 target price on shares of Penumbra in a research note on Thursday, June 11th. Evercore restated an “outperform” rating and issued a $320.00 target price on shares of Penumbra in a research report on Monday, July 6th. Finally, Citigroup decreased their price target on Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $367.07.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.